Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: GATEWAY BIOTECHNOLOGY, INC
Awarding agency: Department of Defense / Defense Health Agency
Funding agency: Department of Defense / Defense Health Agency
Period of performance: 2023-09-18 to 2027-01-17
Current total value of award: $1299999.26
Description: SEQUENTIAL PHASE II SBIR - GW-TT2, A NEW DRUG PRODUCT FOR TINNITUS